Ling Dai

491 total citations
28 papers, 347 citations indexed

About

Ling Dai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Ling Dai has authored 28 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Ling Dai's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ling Dai is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ling Dai collaborates with scholars based in China, Ethiopia and United States. Ling Dai's co-authors include Weiheng Hu, Guangming Tian, Jun Nie, Xiangjuan Ma, Jindi Han, Di Wu, Xiaoling Chen, Sen Han, Jie Zhang and Jian Fang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Cancer.

In The Last Decade

Ling Dai

25 papers receiving 342 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ling Dai 238 136 105 68 53 28 347
Guangming Tian 291 1.2× 172 1.3× 63 0.6× 43 0.6× 54 1.0× 33 357
Xiao Zhao 202 0.8× 130 1.0× 84 0.8× 41 0.6× 67 1.3× 29 323
Weiheng Hu 268 1.1× 154 1.1× 59 0.6× 36 0.5× 52 1.0× 35 334
Xiangjuan Ma 274 1.2× 153 1.1× 62 0.6× 33 0.5× 53 1.0× 34 335
Linpeng Zheng 207 0.9× 150 1.1× 77 0.7× 71 1.0× 37 0.7× 17 304
Shaochuan Liu 237 1.0× 89 0.7× 106 1.0× 54 0.8× 121 2.3× 15 362
Yuto Yasuda 221 0.9× 172 1.3× 121 1.2× 62 0.9× 59 1.1× 35 346
Takashi Nomizo 236 1.0× 175 1.3× 124 1.2× 64 0.9× 57 1.1× 28 354
Ilze Bāra 260 1.1× 225 1.7× 57 0.5× 38 0.6× 40 0.8× 22 365
Patricia Martín-Romano 195 0.8× 102 0.8× 114 1.1× 55 0.8× 31 0.6× 29 306

Countries citing papers authored by Ling Dai

Since Specialization
Citations

This map shows the geographic impact of Ling Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Dai more than expected).

Fields of papers citing papers by Ling Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Dai. The network helps show where Ling Dai may publish in the future.

Co-authorship network of co-authors of Ling Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Dai. A scholar is included among the top collaborators of Ling Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Dai. Ling Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Wenli, Sen Han, Lan Mi, et al.. (2025). Immune checkpoint inhibitor-related myocarditis in patients with lung cancer. BMC Cancer. 25(1). 685–685. 3 indexed citations
2.
Tian, Guangming, Jun Nie, Ling Dai, et al.. (2025). Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China. Frontiers in Oncology. 15. 1577607–1577607.
3.
4.
Zhang, Jie, Liang Wang, Weiheng Hu, et al.. (2023). Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer. Frontiers in Oncology. 13. 829054–829054. 5 indexed citations
5.
Wang, Yang, Jun Nie, Ling Dai, et al.. (2023). Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis. BMC Pulmonary Medicine. 23(1). 172–172. 5 indexed citations
6.
Tian, Guangming, Xinliang Zhao, Jun Nie, et al.. (2022). The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies. Journal of Thoracic Disease. 14(6). 2201–2212. 1 indexed citations
7.
Wang, Yang, Xuanye Zhang, Sen Han, et al.. (2022). Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study. Cancer Medicine. 12(3). 2303–2311. 1 indexed citations
8.
Wang, Yang, Jun Nie, Ling Dai, et al.. (2021). Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. Cancer Immunology Immunotherapy. 71(2). 267–276. 4 indexed citations
9.
Chen, Xiaoling, Jun Nie, Ling Dai, et al.. (2021). Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. Frontiers in Oncology. 11. 607531–607531. 28 indexed citations
10.
Wu, Di, Jun Nie, Weiheng Hu, et al.. (2020). A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. International Journal of Cancer. 147(12). 3453–3460. 29 indexed citations
11.
Dai, Ling, Guangdong Pan, Xiaojia Liu, et al.. (2018). High expression of ALDOA and DDX5 are associated with poor prognosis in human colorectal cancer. Cancer Management and Research. Volume 10. 1799–1806. 38 indexed citations
12.
Wang, Yang, Jun Nie, Ling Dai, et al.. (2018). Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma. Thoracic Cancer. 10(1). 17–23. 7 indexed citations
13.
Tan, Ning, Ling Dai, Xiaojia Liu, et al.. (2017). Upregulation of caprin1 expression is associated with poor prognosis in hepatocellular carcinoma. Pathology - Research and Practice. 213(12). 1563–1567. 21 indexed citations
14.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2017). Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.. Journal of Clinical Oncology. 35(15_suppl). e20574–e20574.
15.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2016). Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine. 95(28). e4183–e4183. 11 indexed citations
16.
Wu, Di, Jian Fang, Jun Nie, et al.. (2015). [Effects of Local Radiation Combined with Chemotherapy in the treatment of 
Patients with Extensive-stage Small Cell Lung Cancer].. SHILAP Revista de lepidopterología. 18(5). 272–9. 2 indexed citations
17.
Zhang, Jie, Jing Gao, Yanyan Li, et al.. (2015). Circulating PD‐L1 in NSCLC patients and the correlation between the level of PD‐L1 expression and the clinical characteristics. Thoracic Cancer. 6(4). 534–538. 109 indexed citations
18.
Zhang, Jie, Jian Fang, Jun Nie, et al.. (2015). Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer.. Journal of Clinical Oncology. 33(15_suppl). e22024–e22024.
19.
Zhang, Jie, Shaolei Li, Jindi Han, et al.. (2014). Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer. Thoracic Cancer. 5(5). 405–410. 10 indexed citations
20.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2014). Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails. Cancer Chemotherapy and Pharmacology. 73(6). 1129–1136. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guangming Tian Breakdown of academic impact, for papers by Xiao Zhao Breakdown of academic impact, for papers by Weiheng Hu Breakdown of academic impact, for papers by Xiangjuan Ma Breakdown of academic impact, for papers by Linpeng Zheng Breakdown of academic impact, for papers by Shaochuan Liu Breakdown of academic impact, for papers by Yuto Yasuda Breakdown of academic impact, for papers by Takashi Nomizo Breakdown of academic impact, for papers by Ilze Bāra Breakdown of academic impact, for papers by Patricia Martín-Romano
Rankless by CCL
2026